Categories Uncategorized

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) Releases Record-Breaking Gross Revenue for January 2021

  • Company reports record gross revenues of C$1,089,502 last month
  • “It is truly encouraging to achieve yet another incredible revenue milestone and to start the new year with such vigor and success,” states CEO
  • Record revenue comes during one of slowest e-commerce periods of year, highlighting impact the company has in the plant-based marketplace

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) saw record gross revenues last month (https://ibn.fm/qro4v). The company released its monthly numbers, noting that gross revenues for January 2021 totaled a record-breaking C$1,089,502; cost of goods sold for the month reached C$751,356.

“It is truly encouraging to achieve yet another incredible revenue milestone and to start the new year with such vigor and success,” said PlantX CEO Julia Frank. “There are many other colorful growth opportunities on the horizon, and we’re confident that our financial trajectory will reflect the remarkable and increasing value our company brings to the plant-based industry.”

PlantX Life stated that its January numbers surpassed its December 2020 gross revenues of $1,029,883, which were achieved during a highly dynamic holiday season. “This was surpassed by January 2021’s revenue, which exceeded management’s expectations given that e-commerce sales were expected to be slower following the holiday season,” the announcement noted. “This success during one of the slowest e-commerce periods of the year highlights the tremendous impact the company continues to have in the plant-based marketplace.” The announcement stated that the company’s growth reflects its commitment to meet consumer demand and continues to be driven by its innovative partnerships as well as its marketing and branding efforts.

As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, PlantX currently has plans to expand its product lines to include cosmetics, clothing and its own water brand.

In addition, the company uses its digital platform to build a community of like-minded consumers and to provide education. Its successful enterprise is being built and fortified through partnerships with top nutritionists, chefs and brands. For example, the company offers 20 unique pre-made meals designed by top chefs and nutritionists. These healthy meals are offered at extremely competitive prices with fast shipping and round-the-clock convenience.

The company’s commitment to customer service is the driving force behind its e-commerce platform, with innovative thinking driving its operation; the PlantX team is constantly envisioning new ways to collaborate with local restaurateurs and entrepreneurs to bring PlantX to the world. PlantX is committed to eliminating the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life.

To learn more about this company, visit www.PlantX.com, www.PlantX.ca and www.Investor.PlantX.com and view the PlantX for Plant-Based Investors.

NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Soligenix Inc. (NASDAQ: SNGX) Advances Ricin Vaccine amid Toxin Threat

A recent report from India is a stark reminder of ricin’s accessibility and the pressing…

1 day ago

US House Passes Republican Healthcare Bill, ACA Extension Left Out

The U.S. House of Representatives passed a healthcare bill that didn’t include an extension of…

1 day ago

Chronic Inflammation Could Be the Missing Key to Understanding Long Covid

In the U.S. about 15 million individuals live with long Covid, according to Department of Health & Human…

2 days ago

Oncotelic Therapeutics Inc. (OTLC) Leverages Nanoparticles to Re-Imagine Drug Delivery in Oncology

Research indicates that the advantages of nanoparticle delivery in pharma are significant Oncotelic Therapeutics has…

3 days ago

Researchers Use Supplements to Produce Remarkable Outcomes in Brain Cancer Treatment

A new study done in India has produced results that bring into question the longstanding assumption that…

4 days ago

Antisense’s Moment: How Rational Design Is Rewriting Drug Development Economics

Industry data shows small molecules achieve 5–10% approval rates over 15–20 years; antisense oligonucleotides (“ASOs”)…

5 days ago